New drug combo shows promise in tough pancreatic cancer trial
NCT ID NCT06492915
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called chiauranib combined with two standard chemotherapy drugs as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival. About 42 adults aged 18 to 75 are participating in this phase 2 trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Blood and gut clues may flag pancreatic cancer risk early
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- A sound wave that could expose hidden pancreatic cancer?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?